Asset profile
Datopotamab Deruxtecan
Antibody–drug conjugate
Evidence outlook
Approved: HR+/HER2- Metastatic Breast Cancer, Non-Small Cell Lung Cancer
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
122 competitors in this universe: 6 direct rivals (same mechanism and indication), 0 same-class, 116 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Datopotamab Deruxtecan: this drug | Approved | Antibody–drug conjugate | TROP2 | ||
| Sacituzumab Govitecan | Approved | Antibody–drug conjugate | TROP2 | ||
| Sacituzumab Tirumotecan | Phase 3 | Antibody–drug conjugate | TROP2 | ||
| DB-1305 | Phase 2 | Antibody–drug conjugate | TROP2 | ||
| BL-M02D1 | Phase 1/2 | Antibody–drug conjugate | TROP2 | ||
| LCB84 | Phase 1/2 | Antibody–drug conjugate | TROP2 | ||
| MT-302 | Phase 1 | Small molecule | TROP2 | ||
| Abemaciclib (Verzenio) | Approved | Small molecule | CDK4 and CDK6 | ||
| Afatinib (Gilotrif) | Approved | Small molecule | EGFR/HER1, HER2, HER4 | ||
| Alectinib (Alecensa) | Approved | Small molecule | ALK | ||
| Alpelisib (BYL719) | Approved | Small molecule | PI3K-alpha | ||
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | ||
| Amivantamab | Approved | Multispecific antibody | EGFR x c-MET | ||
| Anastrozole | Approved | Small molecule | Aromatase | ||
| Atezolizumab | Approved | Monoclonal antibody | PD-L1 | ||
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A |
…and 107 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(33 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (7)
May 2027 (2)
July 2027 (1)
What to watch
September 2027 (2)
October 2027 (1)
What to watch
November 2027 (1)
What to watch
2028 (15)
January 2028 (4)
What to watch
What to watch
What to watch
February 2028 (3)
What to watch
What to watch
What to watch
March 2028 (2)
April 2028 (2)
June 2028 (1)
What to watch
November 2028 (2)
December 2028 (1)
What to watch
2029 (6)
January 2029 (1)
What to watch
April 2029 (1)
What to watch
May 2029 (1)
What to watch
June 2029 (1)
What to watch
August 2029 (1)
What to watch
December 2029 (1)
What to watch
2030 (4)
March 2030 (1)
What to watch
May 2030 (1)
What to watch
September 2030 (1)
What to watch
December 2030 (1)
What to watch
2031 (1)
November 2031 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.